Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cullinan Therapeutics Receives EMA Approval For CLN-978; Phase 1 Study In Active, Difficult-To-Treat Rheumatoid Arthritis To Initiate In Q2 2025

Author: Benzinga Newsdesk | May 08, 2025 07:07am

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025

CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025

Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting

Posted In: CGEM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist